--- title: "Connect Biopharma Holdings (CNTB) news: Nasdaq notice" url: "https://aibio.space/companies/connect-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CNTB Nasdaq notice news: Connect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule." --- CNTB Connect Biopharma Holdings Limited NASDAQ · United States # Connect Biopharma Holdings (CNTB) news CNTB Nasdaq notice news Listings · 2025-07-17 ## [Connect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule](https://aibio.space/news/connect-biopharma-regains-compliance-nasdaq-1-00-minimum-bid-price/) The company's American Depositary Shares closed at $1.00 or more for 10 straight business days, ending a deficiency first flagged on March 24, 2025. ## Latest Connect Biopharma Holdings news We have not published a story on Connect Biopharma Holdings yet. When there is news, it will appear here. ## Connect Biopharma Holdings at a glance - **Ticker**: CNTB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $31.5 million ### Related companies - [Acumen Pharmaceuticals](https://aibio.space/companies/acumen-pharmaceuticals/) NASDAQ: ABOS - [Olema Pharmaceuticals](https://aibio.space/companies/olema-pharmaceuticals/) NASDAQ: OLMA - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA - [Soligenix](https://aibio.space/companies/soligenix/) NASDAQ: SNGX - [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) NASDAQ: VRTX - [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Legend Biotech](https://aibio.space/companies/legend-biotech/) NASDAQ: LEGN ### Also on NASDAQ - [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) AARD - [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) HURA - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) CADL - [Co-Diagnostics](https://aibio.space/companies/diagnostics/) CODX - [Zura Bio](https://aibio.space/companies/zura-bio/) ZURA - [Xenon Pharmaceuticals](https://aibio.space/companies/xenon-pharmaceuticals/) XENE ## What Connect Biopharma Holdings does Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha (IL-4Rα). Rademikibart is a human monoclonal IgG4 antibody that inhibits both interleukin 4 and interleukin 13 signaling by blocking their shared receptor subunit. The company's focus is treatment of acute exacerbations of asthma and COPD. Two Phase 2 trials, Seabreeze STAT ASTHMA and Seabreeze STAT COPD, began in May 2025, and the company expects topline data from them in mid-2026. The FDA aligned on the design of these trials, which compare rademikibart plus standard of care with standard of care plus placebo. In March 2026 the company reported positive topline data from a Phase 1 clinical pharmacology study of intravenous rademikibart in patients with stable asthma or COPD. The text also describes a previously completed global Phase 2b chronic asthma study, CBP-201-WW002, which the company says supports its current development plan. | Product or program | What it is | Stage | |---|---|---| | Rademikibart (acute asthma) | IL-4Rα antibody for acute exacerbations of asthma | Phase 2 | | Rademikibart (acute COPD) | IL-4Rα antibody for acute exacerbations of COPD | Phase 2 | | Rademikibart (chronic asthma) | IL-4Rα antibody tested in a global chronic asthma trial, CBP-201-WW002 | Phase 2b, completed | | Rademikibart (IV) | Intravenous formulation tested in stable asthma and COPD patients | Phase 1, positive topline data March 2026 | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/cntb-20251231.htm). ## Connect Biopharma Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$64,000](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | [$26.0 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | | Research and development | [$37.8 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | [$29.3 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | | Net income (loss) | [-$55.5 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | [-$15.6 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | | Cash from operations | [-$51.2 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | [-$23.6 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | | Cash and equivalents | [$38.3 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000028/) | [$78.2 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | | Short-term investments | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000028/) | [$15.5 million](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $27.0 million, plus short-term investments of $4.5 million, $31.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Connect Biopharma Holdings Has Connect Biopharma Holdings received a Nasdaq deficiency notice? Our latest story on this, dated Jul 17, 2025: "Connect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/connect-biopharma-regains-compliance-nasdaq-1-00-minimum-bid-price/). What is the ticker symbol of Connect Biopharma Holdings? Connect Biopharma Holdings Limited trades under the ticker CNTB on NASDAQ. Where is Connect Biopharma Holdings listed? Connect Biopharma Holdings Limited is listed on NASDAQ. What is the SEC CIK of Connect Biopharma Holdings? The SEC Central Index Key (CIK) for Connect Biopharma Holdings Limited is 1835268. Its filings are on SEC EDGAR. How many shares does Connect Biopharma Holdings have outstanding? 62,974,309 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Connect Biopharma Holdings listed under? Our directory records Connect Biopharma Holdings Limited under United States. What does Connect Biopharma Holdings do? Our directory classifies Connect Biopharma Holdings Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Connect Biopharma Holdings? The ISIN recorded for Connect Biopharma Holdings Limited is KYG235491019. Does aibio.space cover Connect Biopharma Holdings? aibio.space lists Connect Biopharma Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Connect Biopharma Holdings incorporated? SEC records list its state or country of incorporation as E9. What does Connect Biopharma Holdings develop? Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha (IL-4Rα). What is Rademikibart (acute asthma) from Connect Biopharma Holdings? Rademikibart (acute asthma): IL-4Rα antibody for acute exacerbations of asthma Stage: Phase 2. What is Rademikibart (acute COPD) from Connect Biopharma Holdings? Rademikibart (acute COPD): IL-4Rα antibody for acute exacerbations of COPD Stage: Phase 2. What was Connect Biopharma Holdings's revenue last year? $64,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Connect Biopharma Holdings profitable? Connect Biopharma Holdings Limited reported a net loss of $55.5 million for the fiscal year ended Dec 31, 2025, and used $51.2 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Connect Biopharma Holdings Members talk about Connect Biopharma Holdings (CNTB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Connect Biopharma Holdings, newest first. Each line links the filing it comes from. 1. 2026-03-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/exhibit991-phase1ivstudypr.htm) 2. 2025-07-21 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000044/cntb-20250718.htm) 3. 2025-07-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000039/cntb-20250716.htm) 4. 2025-03-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000008/cntb-6xkxex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CNTB on TradingView](https://www.tradingview.com/symbols/NASDAQ-CNTB/). ## SEC filings and registration - **SEC name**: Connect Biopharma Holdings Ltd - **CIK**: 1835268 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CNTB (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, 92130 - **Phone**: 858-727-1040 - **Shares outstanding**: 62,974,309 as of 2026-07-31 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000038/cntb-20260930.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/cntb-20260915.htm) filed 2026-09-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000028/cntb-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/cntb-20260812.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000020/cntb-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/cntb-20260512.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/cntb-20260423.htm) filed 2026-04-23 - [10-K](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/cntb-20251231.htm) filed 2026-03-31 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001835268), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Connect Biopharma Holdings Limited is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CNTB, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Connect Biopharma Holdings Limited - **Ticker**: CNTB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG235491019 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CNTB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/connect-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Connect Biopharma Holdings (CNTB) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/connect-biopharma/